Welcome to the UPF Digital Repository

Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions.

Show simple item record

dc.contributor.author González, Débora
dc.contributor.author Torrens, Marta
dc.contributor.author Farré Albaladejo, Magí
dc.date.accessioned 2016-02-09T12:12:24Z
dc.date.available 2016-02-09T12:12:24Z
dc.date.issued 2015
dc.identifier.citation González D, Torrens M, Farré M. Acute effects of the novel psychoactive drug 2C-B on emotions. Biomed Res Int. 2015;2015:643878. doi: 10.1155/2015/643878.
dc.identifier.issn 2314-6133
dc.identifier.uri http://hdl.handle.net/10230/25759
dc.description.abstract BACKGROUND: 2C-B (Nexus) is one of the most widespread novel psychoactive substances. There is limited information about its pharmacological properties, and few studies in humans concern its acute and chronic effects. 2C-B has been classified as a stimulant, hallucinogen, entactogen, and/or empathogen. OBJECTIVES: To evaluate the emotional, subjective, and cardiovascular effects of 2C-B. METHODS: Twenty healthy recreational 2C-B users (12 women) self-administered a 20 mg dose of 2C-B. Evaluations included emotional (IAPS, FERT, and speech), subjective (visual analog scales, ARCI, VESSPA, HRS, and POMS questionnaires), and cardiovascular effects (blood pressure and heart rate). Results. Positive subjective effects predominated with a reduction of anger under the influence of 2C-B. It did, however, increase reactivity to negative emotional stimuli and decrease the ability to recognize expressions of happiness. Augmented emotionality in speech could be appreciated by others. 2C-B induced euphoria and well-being, changes in perceptions, and slight hallucinogenic states. Mild sympathetic actions were observed./nCONCLUSIONS: The specific profile that 2C-B exerts on emotions suggests its classification as an entactogen with psychedelic properties.
dc.description.sponsorship The paper was supported by grants from Ministerio de Sanidad, Políıtica Social e Igualdad (Plan Nacional sobre Drogas, 2009I047), Ministerio de Economía y Competitividad Instituto de Salud Carlos III (Red de Trastornos Adictivos, UE-FEDER 2012, RD12/0028/0009, and FIS-FEDER, FIS PI11/01961) and The European Commission (Drug Prevention and Information Programme 2014-16, Contract no. JUST/2013/DPIP/AG/4823, EU-MADNESS project).
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Hindawi Publishing Corporation
dc.relation.ispartof BioMed Research International. 2015;2015:643878
dc.rights © 2015 Débora González et al. This is an open access article distributed under the http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.rights.uri http://creativecommons.org/licenses/by/3.0/
dc.subject.other Medicaments -- Efectes secundaris
dc.title Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions.
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1155/2015/643878
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking